Robert J. Bitterman, Chairman, President & CEO at Phio Pharmaceuticals Corp. (PHIO), bought 10,000 shares at $1.06 ($11K) on 2026-08-18, disclosed to the SEC on 2026-08-19.
Chairman and CEO Robert J. Bitterman purchased 10,000 shares at $1.06 on August 18, 2026, signaling confidence in the company's valuation following a significant insider buying event. This marks the largest purchase in the company's history, potentially indicating that the stock has bottomed out.
The stock is trading at $1.05, down 3.67% over the last five days and 4.11% over the last 90 days, but remains 24.2% above its 52-week low of $0.8454.
1) Upcoming Q3 earnings on October 29, 2026; 2) The company received a patent grant decision on July 15, 2026, strengthening its INTASYL® platform; 3) This represents the largest insider purchase ever recorded.
The stock is down 14.63% from its 52-week high of $1.23, and short interest remains elevated at 2.48% of the float.
Something here stands out, but not much.
| Filing → |
| PHIO | BUY | 2025-12-29 | $5K | — | Filing → |
| PHIO | BUY | 2025-11-24 | $6K | — | Filing → |
| PHIO | BUY | 2025-11-19 | $6K | — | Filing → |